NCT03374202View on ClinicalTrials.gov

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 11, 2018

Primary Completion Date

August 8, 2026

Study Completion Date

August 8, 2026

Conditions
HIV-1 Infected Adults With Controlled Viremia
Interventions
GENETIC

VRC-HIVAAV070-00-GT (AAV8-VRC07)

AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH